You are here:

naloxegol (Moventig)

Advice

following a full submission

naloxegol (Moventig®) is accepted for use within NHS Scotland.

Indication under review: the treatment of opioid-induced constipation in adult patients who have had an inadequate response to laxative(s).

Naloxegol compared to placebo significantly improved the response rate in patients with opioid-induced constipation including patients who had previously had an inadequate response to at least four days of treatment with at least one class of laxative.

Drug Details

Drug Name: naloxegol (Moventig)
SMC Drug ID: 1106/15
Manufacturer: AstraZeneca UK Ltd
Indication: the treatment of opioid-induced constipation in adult patients who have had an inadequate response to laxative(s).
BNF Category:
Sub Category: 1.6 Laxatives
Submission Type: Full submission
Status: Accepted
Date Advice Published: 7 December 2015

Back